Insider Trading Alert - TIPT, VER And CUR Traded By Insiders

Stocks with insider trader activity include TIPT, VER and CUR
By TheStreet Wire ,

Yesterday, Nov. 16, 2015, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,470.50 to $10,820,124.97.

Highlighted Stocks Traded by Insiders:

Tiptree Financial (TIPT) - FREE Research Report

Barnes Michael Gene, who is Executive Chairman at Tiptree Financial, bought 5,000 shares at $6.59 on Nov. 16, 2015. Following this transaction, the Executive Chairman owned 3.2 million shares meaning that the stake was boosted by 0.16% with the 5,000-share transaction.

The shares most recently traded at $6.99, up $0.40, or 5.66% since the insider transaction. Historical insider transactions for Tiptree Financial go as follows:

  • 4-Week # shares bought: 38,290
  • 12-Week # shares bought: 132,950
  • 24-Week # shares bought: 284,625

The average volume for Tiptree Financial has been 40,600 shares per day over the past 30 days. Tiptree Financial has a market cap of $216.4 million and is part of the financial sector and insurance industry. Shares are down 20% year-to-date as of the close of trading on Monday.

TipTree Financial Inc., formerly Care Investment Trust, operates as a real estate investment trust (REIT). It engages in originating and acquiring healthcare-related real estate and commercial mortgage debt. The stock currently has a dividend yield of 1.54%.

Exclusive Offer: Get the latest Stock Analysis on TIPT - FREE

TheStreet Quant Ratings

rates Tiptree Financial as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Tiptree Financial Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

VEREIT (VER) - FREE Research Report

Pinover Eugene A, who is Director at VEREIT, bought 12,300 shares at $8.12 on Nov. 16, 2015. Following this transaction, the Director owned 21,298 shares meaning that the stake was boosted by 136.7% with the 12,300-share transaction.

The shares most recently traded at $8.05, down $0.06, or 0.81% since the insider transaction. Historical insider transactions for VEREIT go as follows:

  • 4-Week # shares bought: 30,500
  • 4-Week # shares sold: 53,184
  • 12-Week # shares bought: 30,500
  • 12-Week # shares sold: 53,184
  • 24-Week # shares bought: 150,500
  • 24-Week # shares sold: 53,184

The average volume for VEREIT has been 5.3 million shares per day over the past 30 days. VEREIT has a market cap of $8.0 billion and is part of the financial sector and real estate industry. Shares are down 8.84% year-to-date as of the close of trading on Friday.

VEREIT, Inc. is a publicly owned real estate investment trust. It owns and acquires single tenant, freestanding commercial real estate that is net leased on a medium-term basis, primarily to investment grade credit rated and other creditworthy tenants. The stock currently has a dividend yield of 6.42%. Currently, there is 1 analyst who rates VEREIT a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VER - FREE

TheStreet Quant Ratings

rates VEREIT as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

VEREIT Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Neuralstem (CUR) - FREE Research Report

Johe Karl, who is Chief Scientific Officer at Neuralstem, sold 25,000 shares at $1.09 on Nov. 16, 2015. Following this transaction, the Chief Scientific Officer owned 826,304 shares meaning that the stake was reduced by 2.94% with the 25,000-share transaction.

The shares most recently traded at $1.10, up $0.01, or 0.91% since the insider transaction. Historical insider transactions for Neuralstem go as follows:

  • 4-Week # shares bought: 14,250
  • 4-Week # shares sold: 75,000
  • 12-Week # shares bought: 14,250
  • 12-Week # shares sold: 200,000
  • 24-Week # shares bought: 14,250
  • 24-Week # shares sold: 200,000

The average volume for Neuralstem has been 401,000 shares per day over the past 30 days. Neuralstem has a market cap of $100.0 million and is part of the health care sector and drugs industry. Shares are down 59.93% year-to-date as of the close of trading on Monday.

Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds. Currently, there are 2 analysts who rate Neuralstem a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CUR - FREE

TheStreet Quant Ratings

rates Neuralstem as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Neuralstem Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...